-
M.
Beresford,
I.
Tumur,
J.
Chakrabarti,
J.
Barden,
N.
Rao,
A.
Makris
(2011)
A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer.
Clinical oncology (Royal College of Radiologists (Great Britain)), 23 3
-
J.
Robertson,
A.
Llombart-Cussac,
J.
Rolski,
D.
Feltl,
J.
Dewar,
E.
Macpherson,
J.
Lindemann,
M.
Ellis
(2009)
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 27
-
(2000)
Phase Ib/II trial of LEE011 with everolimus (RAD001) and exemestane in the treatment of ER+ Her2− advanced breast cancer
ClinicalTrials.gov [Internet]
-
J.
Baselga,
M.
Campone,
M.
Piccart,
H.
Burris,
H.
Rugo,
T.
Sahmoud,
S.
Noguchi,
M.
Gnant,
K.
Pritchard,
F.
Lebrun,
J.
Beck,
Yoshinori
Ito,
D.
Yardley,
I.
Deleu,
Alejandra
Perez,
T.
Bachelot,
L.
Vittori,
Zhi-Xia
Xu,
P.
Mukhopadhyay,
D.
Lebwohl,
G.
Hortobagyi
(2012)
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
The New England journal of medicine, 366 6
-
Atif
Khan,
B.
Haffty
(2012)
Issues in the curative therapy of breast cancer in elderly women.
Seminars in radiation oncology, 22 4
-
PD 0332991 and anastrozole for stage 2 or 3 estrogen receptor positive and HER2 negative breast cancer
-
W.
Water,
C.
Markopoulos,
C.
Velde,
C.
Seynaeve,
A.
Hasenburg,
D.
Rea,
H.
Putter,
J.
Nortier,
A.
Craen,
E.
Hille,
E.
Bastiaannet,
P.
Hadji,
R.
Westendorp,
G.
Liefers,
Stephen
Jones
(2012)
Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.
JAMA, 307 6
-
(2012)
Faslodex (fulvestrant) injection
-
(2000)
Phase Ib/II trial of LEE011 with everolimus (RAD001) and exemestane in the treatment of ER+ Her2- advanced breast cancer. In: ClinicalTrials.gov [Internet
-
(2004)
Aromasin (exemestane tablets)
-
P.
Mansky,
S.
Straus
(2002)
St. John's Wort: more implications for cancer patients.
Journal of the National Cancer Institute, 94 16
-
S.
O'brien,
E.
Berman,
H.
Borghaei,
D.
DeAngelo,
Marcel
Devetten,
S.
Devine,
Harry
Erba,
J.
Gotlib,
M.
Jagasia,
Joseph
Moore,
T.
Mughal,
J.
Pinilla-Ibarz,
J.
Radich,
Neil
Shah,
Paul
Shami,
B.
Smith,
David
Snyder,
Martin
Tallman,
M.
Talpaz,
M.
Wetzler
(2009)
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN, 7 9
-
M.
Kemeny,
B.
Peterson,
A.
Kornblith,
H.
Muss,
Judith
Wheeler,
E.
Levine,
N.
Bartlett,
G.
Fleming,
H.
Cohen
(2003)
Barriers to clinical trial participation by older women with breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 12
-
I.
Smith,
J.
Pierga,
L.
Biganzoli,
H.
Cortés-Funes,
C.
Thomssen,
X.
Pivot,
A.
Fabi,
Binghe
Xu,
D.
Stroyakovskiy,
F.
Franke,
Bella
Kaufman,
Paul
Mainwaring,
T.
Pieńkowski,
B.
Valk,
A.
Kwong,
J.
González-Trujillo,
I.
Koza,
Katarína
Petráková,
D.
Pereira,
Kathleen
Pritchard
(2011)
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
Annals of oncology : official journal of the European Society for Medical Oncology, 22 3
-
N.
Dubrawsky
(1989)
Cancer statistics
CA: A Cancer Journal for Clinicians, 39
-
(2012)
Tykerb (lapatinib) tablets
-
C.
Falandry,
E.
Brain,
M.
Bonnefoy,
F.
Mefti,
N.
Jovenin,
O.
Rigal,
O.
Guillem,
C.
Kouri,
L.
Uwer,
S.
Abadie-Lacourtoisie,
J.
Cretin,
J.
Jacquin,
D.
Paraiso,
G.
Freyer
(2013)
Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial.
European journal of cancer, 49 13
-
T.
Jolly,
G.
Williams,
Ellen
Jones,
H.
Muss
(2012)
Treatment of Metastatic Breast Cancer in Women Aged 65 Years and Older
Women's Health, 8
-
G.
Riley,
J.
Warren,
L.
Harlan,
S.
Blackwell
(2011)
Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D.
Medicare & medicaid research review, 1 4
-
Carlos
Barrios,
John
Forbes,
Walter
Jonat,
Pierfranco
Conte,
W.
Gradishar,
Aman
Buzdar,
K.
Gelmon,
M.
Gnant,
J.
Bonneterre,
M.
Toi,
C.
Hudis,
J.
Robertson
(2012)
The sequential use of endocrine treatment for advanced breast cancer: where are we?
Annals of oncology : official journal of the European Society for Medical Oncology, 23 6
-
C.
Oakman,
E.
Moretti,
L.
Santarpia,
A.
Leo
(2011)
Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
Future oncology, 7 2
-
L.
Biganzoli,
E.
Vincenzo,
Z.
Jiang,
M.
Lichinitser,
Z.
Shen,
R.
Delva,
N.
Bogdanova,
G.
Vivanco,
Z.
Chen,
Y.
Cheng,
M.
Just,
M.
Espié,
J.
Vinholes,
C.
Hamm,
D.
Crivellari,
E.
Chmielowska,
V.
Semiglazov,
F.
Dalenc,
I.
Smith
(2012)
First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study.
Annals of oncology : official journal of the European Society for Medical Oncology, 23 1
-
J.
Rodón,
R.
Dienstmann,
V.
Serra,
J.
Tabernero
(2013)
Development of PI3K inhibitors: lessons learned from early clinical trials
Nature Reviews Clinical Oncology, 10
-
G.
Tinoco,
S.
Warsch,
S.
Glück,
Kiran
Avancha,
A.
Montero
(2013)
Treating Breast Cancer in the 21st Century: Emerging Biological Therapies
Journal of Cancer, 4
-
J.
Braybrooke
(2013)
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
-
(2000)
Pfizer Phase III study of palbociclib (PD-0332991) in combination with exemestane versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to non-steroidal aromatase inhibitors (PEARL)
ClinicalTrials.gov [Internet]
-
Jinjia
Chang,
W.
Fan
(2013)
Endocrine therapy resistance: current status, possible mechanisms and overcoming strategies.
Anti-cancer agents in medicinal chemistry, 13 3
-
(2008)
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT
J Clin Oncol, 26
-
R.
Audisio
(2011)
Breast cancer in the elderly: different treatment modalities.
European journal of cancer, 47 Suppl 3
-
A study of palbociclib (PD-0332991) + letrozole vs. letrozole for 1st line treatment of postmenopausal women with ER+/HER2-advanced breast cancer (PALOMA-2)
-
R.
Carlson,
Susan
Moench,
A.
Hurria,
L.
Balducci,
H.
Burstein,
L.
Goldstein,
W.
Gradishar,
K.
Hughes,
M.
Jahanzeb,
S.
Lichtman,
L.
Marks,
J.
Mcclure,
B.
McCormick,
L.
Nabell,
L.
Pierce,
M.
Smith,
N.
Topham,
T.
Traina,
J.
Ward,
E.
Winer
(2008)
NCCN Task Force Report: breast cancer in the older woman.
Journal of the National Comprehensive Cancer Network : JNCCN, 6 Suppl 4
-
H.
Wildiers,
I.
Kunkler,
L.
Biganzoli,
J.
Fracheboud,
G.
Vlastos,
C.
Bernard‐Marty,
A.
Hurria,
M.
Extermann,
V.
Girre,
E.
Brain,
R.
Audisio,
H.
Bartelink,
M.
Barton,
S.
Giordano,
H.
Muss,
M.
Aapro
(2007)
Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology.
The Lancet. Oncology, 8 12
-
T.
Reimer,
B.
Gerber
(2010)
Quality-of-Life Considerations in the Treatment of Early-Stage Breast Cancer in the Elderly
Drugs & Aging, 27
-
(2004)
New York, NY: Pharmacia and Upjohn Company
-
M.
Debled,
C.
Bellera,
C.
Donamaria,
P.
Soubeyran
(2011)
Chemotherapy treatment for older women with metastatic breast cancer: what is the evidence?
Cancer treatment reviews, 37 8
-
Jeannie
Yoon,
J.
Malin,
M.
Tao,
D.
Tisnado,
J.
Adams,
Martha
Timmer,
P.
Ganz,
K.
Kahn
(2007)
Symptoms after breast cancer treatment: are they influenced by patient characteristics?
Breast Cancer Research and Treatment, 108
-
L.
Ries,
D.
Harkins,
Martin
Krapcho,
A.
Mariotto,
B.
Miller,
E.
Feuer,
L.
Clegg,
M.
Eisner,
Marie-Josèphe
Horner,
N.
Howlader,
Matthew
Hayat,
B.
Hankey,
B.
Edwards
(2006)
SEER Cancer Statistics Review, 1975-2003
-
M.
Gnant
(2012)
Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition
Expert Review of Anticancer Therapy, 12
-
F.
Cardoso,
A.
Costa,
L.
Norton,
D.
Cameron,
T.
Čufer,
L.
Fallow,
eld,
P.
Francis,
J.
Gligorov,
S.
Kyriakides,
N.
Lin,
O.
Pagani,
E.
Senkus,
C.
Thomssenm,
M.
Aapro,
J.
Bergh,
A.
Leo,
N.
Saghir,
P.
Ganz,
K.
Gelmon,
A.
Goldhirsch,
N.
Harbeck,
N.
Houssami,
C.
Hudis,
B.
Kaufman,
M.
Leadbeater,
M.
Mayer,
A.
Rodger,
V.
Sacchini,
G.
Sledge,
G.
Viale,
ff,
I.
Krop,
E.
Winer
(2012)
International consensus guidelines for advanced breast cancer ( ABC 1 )
-
(2006)
Femara (letrozole tablets) 2.5 mg tablets. East Hanover, NJ: Novartis Pharmaceuticals Corporation
-
(2014)
NCCN Clinical Practice Guidelines in Oncology
Breast Cancer. Version 1.2014
-
J.
Brollo,
G.
Curigliano,
D.
Disalvatore,
B.
Marrone,
C.
Criscitiello,
V.
Bagnardi,
M.
Kneubil,
L.
Fumagalli,
M.
Locatelli,
S.
Manunta,
A.
Goldhirsch
(2013)
Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials.
Cancer treatment reviews, 39 1
-
N.
Wilcken,
R.
Dear
(2008)
Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007.
European journal of cancer, 44 15
-
N.
Turner,
F.
André,
S.
Loibl,
J.
Ro,
H.
Iwata,
N.
Harbeck,
S.
Glück,
S.
Verma,
S.
Loi,
C.
Bartlett,
A.
Thiele,
Ke
Zhang,
M.
Koehler,
M.
Cristofanilli
(2013)
Abstract OT3-2-10: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy
Cancer Research, 73
-
R.
Riemsma,
Carol
Forbes,
A.
Kessels,
K.
Lykopoulos,
M.
Amonkar,
Daniel
Rea,
Jos
Kleijnen
(2010)
Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer
Breast Cancer Research and Treatment, 123
-
L.
Gibson,
C.
Dawson,
D.
Lawrence,
J.
Bliss
(2007)
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
The Cochrane database of systematic reviews, 1
-
G.
Bhattacharvva,
J.
Biswas,
Jagpreet
Singh,
M.
Singh,
K.
Govindbabu,
A.
Ranade,
H.
Malhotra,
P.
Parikh,
T.
Shahid,
S.
Basu
(2011)
Reversal of Tamoxifen Resistance (Hormone Resistance) by Addition of Sirolimus (mTOR Inhibitor) in Metastatic Breast Cancer
European Journal of Cancer, 47
-
L.
Biganzoli,
H.
Wildiers,
C.
Oakman,
L.
Marotti,
S.
Loibl,
I.
Kunkler,
M.
Reed,
S.
Ciatto,
A.
Voogd,
E.
Brain,
B.
Cutuli,
C.
Terret,
M.
Gosney,
M.
Aapro,
R.
Audisio
(2012)
Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA).
The Lancet. Oncology, 13 4
-
D.
Pfister,
K.
Ang,
D.
Brizel
(2012)
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
-
Radha
Munagala,
F.
Aqil,
Ramesh
Gupta
(2011)
Promising molecular targeted therapies in breast cancer
Indian Journal of Pharmacology, 43
-
B.
Kaufman,
J.
Mackey,
M.
Clemens,
P.
Bapsy,
A.
Vaid,
A.
Wardley,
S.
Tjulandin,
M.
Jahn,
M.
Lehle,
A.
Feyereislova,
C.
Révil,
A.
Jones
(2009)
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 33
-
C.
Sanchez,
Cynthia
Ma,
R.
Crowder,
Therese
Guintoli,
C.
Phommaly,
F.
Gao,
Li
Lin,
M.
Ellis
(2011)
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
Breast Cancer Research : BCR, 13
-
C.
Villarreal-Garza,
J.
Cortes,
F.
André,
S.
Verma
(2012)
mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.
Annals of oncology : official journal of the European Society for Medical Oncology, 23 10
-
P.
Lønning,
E.
Bajetta,
R.
Murray,
M.
Tubiana‐Hulin,
P.
Eisenberg,
E.
Mickiewicz,
L.
Celio,
P.
Pitt,
M.
Mita,
N.
Aaronson,
C.
Fowst,
A.
Arkhipov,
E.
Salle,
A.
Polli,
G.
Massimini
(2000)
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 11
-
Susan
Cleator,
E.
Ahamed,
R.
Coombes,
R.
Coombes,
Carlo
Palmieri,
Carlo
Palmieri
(2009)
A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.
Clinical breast cancer, 9 Suppl 1
-
D.
Yardley,
S.
Noguchi,
K.
Pritchard,
H.
Burris,
J.
Baselga,
M.
Gnant,
G.
Hortobagyi,
M.
Campone,
B.
Pistilli,
M.
Piccart,
B.
Melichar,
K.
Petráková,
F.
Arena,
F.
Erdkamp,
W.
Harb,
W.
Feng,
A.
Cahana,
T.
Taran,
D.
Lebwohl,
H.
Rugo
(2013)
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
Advances in Therapy, 30
-
H.
Baker
(2014)
2013 San Antonio Breast Cancer Symposium.
The Lancet. Oncology, 15 2
-
H.
Muss,
J.
Busby‐Whitehead
(2011)
Older women with breast cancer: slow progress, great opportunity, now is the time.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 35
-
M.
Daidone,
D.
Coradini,
G.
Martelli,
S.
Veneroni
(2003)
Primary breast cancer in elderly women: biological profile and relation with clinical outcome.
Critical reviews in oncology/hematology, 45 3
-
S.
Johnston
(2010)
New Strategies in Estrogen Receptor–Positive Breast Cancer
Clinical Cancer Research, 16
-
F.
Cardoso,
E.
Senkus-Konefka,
L.
Fallowfield,
A.
Costa,
M.
Castiglione
(2010)
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 5
-
Lanell
Bellury,
M.
Pett,
L.
Ellington,
S.
Beck,
Jane
Clark,
K.
Stein
(2012)
The effect of aging and cancer on the symptom experience and physical function of elderly breast cancer survivors
Cancer, 118
-
J.
Huober,
J.
Huober,
P.
Fasching,
P.
Fasching,
M.
Barsoum,
L.
Petruželka,
D.
Wallwiener,
C.
Thomssen,
T.
Reimer,
S.
Paepke,
H.
Azim,
V.
Ragosch,
E.
Kubista,
A.
Baumgärtner,
M.
Beckmann,
C.
May,
I.
Nimmrich,
N.
Harbeck
(2012)
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.
Breast, 21 1
-
(2007)
Nolvadex (tamoxifen citrate tablet)
-
S.
Harichand-Herdt,
A.
Zelnak,
R.
O'Regan
(2009)
Endocrine therapy for the treatment of postmenopausal women with breast cancer
Expert Review of Anticancer Therapy, 9
-
(2000)
Open-label, phase II, study of everolimus plus letrozole in postmenopausal women with ER+, HER2− metastatic or locally advanced breast cancer (Bolero-4)
ClinicalTrials.gov [Internet]
-
A.
Wolff,
A.
Lazar,
I.
Bondarenko,
A.
Garin,
S.
Brincat,
L.
Chow,
Yan
Sun,
Z.
Nešković‐Konstantinović,
R.
Guimarães,
P.
Fumoleau,
A.
Chan,
S.
Hachemi,
A.
Strahs,
M.
Cincotta,
A.
Berkenblit,
M.
Krygowski,
Lih
Kang,
L.
Moore,
D.
Hayes
(2013)
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 2
-
(2000)
Study of combined fulvestrant and everolimus in advanced / metastatic breast cancer after aromatase inhibitor failure ( BRE43 )
-
M.
Vetter,
D.
Huang,
G.
Bosshard,
U.
Güth
(2013)
Breast cancer in women 80 years of age and older: A comprehensive analysis of an underreported entity
Acta Oncologica, 52
-
J.
Woodcock,
R.
Behrman,
A.
Lindsay,
R.
Choudhury,
R.
Wetsel
(2011)
Mechanisms of endocrine resistance in breast cancer.
Annual review of medicine, 62
-
(2014)
Afinitor Disperz (everolimus tablets for oral suspension)
-
R.
Finn,
J.
Crown,
I.
Láng,
K.
Boér,
I.
Bondarenko,
Sergey
Kulyk,
J.
Ettl,
Ravi
Patel,
T.
Pintér,
Marcus
Schmidt,
Y.
Shparyk,
A.
Thummala,
N.
Voytko,
C.
Fowst,
Xin
Huang,
Sindy
Kim,
S.
Randolph,
D.
Slamon
(2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
The Lancet. Oncology, 16 1
-
M.
Hamaker,
B.
Buurman,
B.
Munster,
Ingeborg
Kuper,
C.
Smorenburg,
S.
Rooij
(2011)
The value of a comprehensive geriatric assessment for patient care in acutely hospitalized older patients with cancer.
The oncologist, 16 10
-
M.
Aapro,
S.
Monfardini,
A.
Jirillo,
U.
Basso
(2009)
Management of primary and advanced breast cancer in older unfit patients (medical treatment).
Cancer treatment reviews, 35 6
-
M.
Aapro,
C.
Bernard‐Marty,
E.
Brain,
G.
Batist,
F.
Erdkamp,
K.
Krzemieniecki,
R.
Leonard,
A.
Lluch,
S.
Monfardini,
M.
Ryberg,
P.
Soubeyran,
U.
Wedding
(2011)
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.
Annals of oncology : official journal of the European Society for Medical Oncology, 22 2
-
R.
Mehta,
W.
Barlow,
K.
Albain,
T.
Vandenberg,
S.
Dakhil,
Nagendra
Tirumali,
D.
Lew,
D.
Hayes,
J.
Gralow,
R.
Livingston,
G.
Hortobagyi
(2012)
Combination anastrozole and fulvestrant in metastatic breast cancer.
The New England journal of medicine, 367 5
-
P.
Tran,
I.
Fentiman
(2009)
Better treatment for breast cancer in older patients
Expert Review of Anticancer Therapy, 9
-
J.
Jurado,
P.
Aznar,
J.
Mata,
R.
Martínez,
I.
Fernández,
Teresa
Gimeno,
E.
Calvo,
L.
Jaso,
E.
Marqués,
A.
Palomo
(2011)
Management of patients with metastatic breast cancer.
Advances in Therapy, 28
-
Novartis Pharmaceuticals. Study of LEE011, BYL719 and letrozole in advanced ER+ breast cancer
-
(2013)
American Cancer Society Breast Cancer Facts and Figures 2013–2014
-
B.
Beadle,
W.
Woodward,
T.
Buchholz
(2011)
The impact of age on outcome in early-stage breast cancer.
Seminars in radiation oncology, 21 1
-
(2014)
Afinitor (everolimus tablets for oral administration) Afinitor Disperz (everolimus tablets for oral suspension). East Hanover, NJ: Novartis Pharmaceuticals Corporation
-
F.
Cardoso,
A.
Costa,
E.
Senkus,
M.
Aapro,
F.
André,
C.
Barrios,
J.
Bergh,
G.
Bhattacharyya,
L.
Biganzoli,
M.
Cardoso,
L.
Carey,
D.
Corneliussen-James,
G.
Curigliano,
V.
Diéras,
N.
Saghir,
A.
Eniu,
L.
Fallowfield,
D.
Fenech,
P.
Francis,
K.
Gelmon,
A.
Gennari,
N.
Harbeck,
C.
Hudis,
B.
Kaufman,
I.
Krop,
M.
Mayer,
H.
Meijer,
S.
Mertz,
S.
Ohno,
O.
Pagani,
E.
Papadopoulos,
F.
Peccatori,
F.
Penault-Llorca,
M.
Piccart,
J.
Pierga,
H.
Rugo,
L.
Shockney,
G.
Sledge,
S.
Swain,
C.
Thomssen,
A.
Tutt,
D.
Vorobiof,
Bing-he
Xu,
L.
Norton,
Eric
Winer
(2017)
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).
Breast, 31
-
(2000)
Study of LEE011, BYL719 and letrozole in advanced ER+ breast cancer
ClinicalTrials.gov [Internet]
-
L.
Malorni,
G.
Sanna,
M.
Pestrin,
O.
Siclari,
L.
Biganzoli,
C.
Biagioni,
S.
Cappadona,
I.
Migliaccio,
C.
Guarducci,
L.
Boni,
D.
Baldari,
A.
Minisini,
G.
Curigliano,
M.
Koehler,
M.
Buyse,
A.
Leo
(2013)
Abstract OT2-6-01: Phase 2 study of palbociclib (CDK 4/6 inhibitor) for ER positive, HER2- negative post-menopausal advanced breast cancer patients recurring after hormonal therapy (to reverse endocrine resistance - TREnd trial)
Cancer Research, 73
-
G.
Williams,
Ellen
Jones,
H.
Muss
(2013)
Challenges in the treatment of older breast cancer patients.
Hematology/oncology clinics of North America, 27 4
-
A.
Goldhirsch,
E.
Winer,
A.
Coates,
R.
Gelber,
M.
Piccart-Gebhart,
B.
Thürlimann,
H.
Senn,
K.
Albain,
F.
André,
J.
Bergh,
H.
Bonnefoi,
Denisse
Bretel-Morales,
H.
Burstein,
F.
Cardoso,
M.
Castiglione‐Gertsch,
A.
Coates,
M.
Colleoni,
Alberto
Costa,
G.
Curigliano,
N.
Davidson,
A.
Leo,
B.
Ejlertsen,
J.
Forbes,
R.
Gelber,
M.
Gnant,
A.
Goldhirsch,
P.
Goodwin,
P.
Goss,
J.
Harris,
D.
Hayes,
C.
Hudis,
J.
Ingle,
J.
Jassem,
Zefei
Jiang,
P.
Karlsson,
S.
Loibl,
M.
Morrow,
M.
Namer,
C.
Osborne,
A.
Partridge,
F.
Penault-Llorca,
C.
Perou,
M.
Piccart-Gebhart,
K.
Pritchard,
E.
Rutgers,
F.
Sedlmayer,
V.
Semiglazov,
Z.
Shao,
I.
Smith,
B.
Thürlimann,
M.
Toi,
A.
Tutt,
M.
Untch,
G.
Viale,
Toru
Watanabe,
N.
Wilcken,
Eric
Winer,
W.
Wood
(2013)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Annals of Oncology, 24
-
David
Cameron,
D.
Camidge,
James
Oyee,
M.
Hirsch
(2008)
Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer
British Journal of Cancer, 99
-
H.
Mouridsen,
H.
Chaudri-Ross
(2004)
Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
The oncologist, 9 5
-
C.
Owusu,
D.
Buist,
T.
Field,
T.
Lash,
S.
Thwin,
A.
Geiger,
V.
Quinn,
F.
Frost,
M.
Prout,
M.
Yood,
F.
Wei,
R.
Silliman
(2008)
Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 4
-
K.
Kahn,
E.
Schneider,
J.
Malin,
J.
Adams,
A.
Epstein
(2007)
Patient Centered Experiences in Breast Cancer: Predicting Long-Term Adherence to Tamoxifen Use
Medical Care, 45
-
M.
Kartal,
S.
Tezcan,
T.
Canda
(2013)
Diagnosis, treatment characteristics, and survival of women with breast cancer aged 65 and above: a hospital-based retrospective study
BMC Women's Health, 13
-
A.
Howell,
J.
Robertson,
P.
Abram,
M.
Lichinitser,
R.
Elledge,
E.
Bajetta,
Toru
Watanabe,
C.
Morris,
A.
Webster,
I.
Dimery,
C.
Osborne
(2004)
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 9
-
G.
Bertelli,
O.
Garrone,
M.
Merlano,
M.
Occelli,
L.
Bertolotti,
F.
Castiglione,
F.
Pepi,
O.
Fusco,
L.
Mastro,
R.
Leonard
(2006)
Sequential Treatment with Exemestane and Non-Steroidal Aromatase Inhibitors in Advanced Breast Cancer
Oncology, 69
-
Clinical Medicine Insights: Oncology
-
G.
Aprile,
L.
Ferrari,
C.
Fontanella,
F.
Puglisi
(2013)
Bevacizumab in older patients with advanced colorectal or breast cancer.
Critical reviews in oncology/hematology, 87 1
-
C.
Lange,
D.
Yee
(2011)
Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer.
Endocrine-related cancer, 18 4
-
S.
Glück,
G.
Minckwitz,
M.
Untch
(2013)
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
Breast, 22 2
-
S.
Johnston,
J.
Pippen,
X.
Pivot,
M.
Lichinitser,
S.
Sadeghi,
V.
Diéras,
H.
Gómez,
G.
Romieu,
A.
Manikhas,
M.
Kennedy,
M.
Press,
J.
Maltzman,
A.
Florance,
L.
O’Rourke,
C.
Oliva,
S.
Stein,
M.
Pegram
(2009)
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 33
-
C.
Osborne,
J.
Pippen,
S.
Jones,
Leroy
Parker,
M.
Ellis,
S.
Come,
Stan
Gertler,
J.
May,
Gary
Burton,
I.
Dimery,
A.
Webster,
C.
Morris,
R.
Elledge,
Aman
Buzdar
(2002)
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 16
-
K.
Pritchard,
H.
Burris,
Yoshinori
Ito,
H.
Rugo,
S.
Dakhil,
G.
Hortobagyi,
M.
Campone,
T.
Csöszi,
J.
Baselga,
P.
Puttawibul,
M.
Piccart,
D.
Heng,
S.
Noguchi,
V.
Srimuninnimit,
H.
Bourgeois,
Antonio
Martín,
K.
Osborne,
A.
Panneerselvam,
T.
Taran,
T.
Sahmoud,
M.
Gnant
(2013)
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Clinical breast cancer, 13 6
-
J.
Flemming,
Y.
Madarnas,
J.
Franek
(2009)
Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review
Breast Cancer Research and Treatment, 115
-
B.
Beuselinck,
H.
Wildiers,
W.
Wynendaele,
L.
Dirix,
J.
Kains,
R.
Paridaens
(2010)
Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology.
Critical reviews in oncology/hematology, 75 1
-
(2000)
Open-label, phase II, study of everolimus plus letrozole in postmenopausal women with ER+, HER2- metastatic or locally advanced breast cancer (Bolero-4). In: ClinicalTrials.gov [Internet
-
Milton
stood,
Joseph
Wittreich,
T.
Hayes
(1883)
The University of Maryland
The American Journal of Dental Science, 17
-
(2000)
Phase III study of BKM120/placebo with fulvestrant in postmenopausal patients with hormone receptor positive HER2− negative locally advanced or metastatic breast cancer refractory to aromatase inhibitor (BELLE-2)
ClinicalTrials.gov [Internet]
-
P.
Dialla,
T.
Dabakuyo,
S.
Marilier,
J.
Gentil,
P.
Roignot,
A.
Darut‐Jouve,
Marie‐Laure
Poillot,
V.
Quipourt,
P.
Arveux
(2012)
Population-based study of breast cancer in older women: prognostic factors of relative survival and predictors of treatment
BMC Cancer, 12
-
A Phase III study of BKM120 with fulvestrant in patients with HR+,HER2-, AI treated, locally advanced or metastatic breast cancer who progressed on or after mTORi (BELLE-3)
-
J.
Bergh,
P.
Jönsson,
E.
Lidbrink,
M.
Trudeau,
W.
Eiermann,
D.
Brattström,
J.
Lindemann,
F.
Wiklund,
R.
Henriksson
(2012)
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 16
-
C.
Markopoulos,
W.
Water,
C.
Velde
(2013)
Breast cancer in the elderly: reducing the losses.
Future oncology, 9 9
-
S.
Johnston,
G.
Saccani‐Jotti,
I.
Smith,
J.
Salter,
J.
Newby,
M.
Coppen,
S.
Ebbs,
M.
Dowsett
(1995)
Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.
Cancer research, 55 15
-
R.
Chlebowski
(2014)
Strategies to overcome endocrine therapy resistance in hormone receptor-positive advanced breast cancer
Clinical investigation, 4
-
M.
Malik,
P.
Tartter,
R.
Belfer
(2013)
Undertreated Breast Cancer in the Elderly
Journal of Cancer Epidemiology, 2013
-
W.
Barry,
A.
Moreno-Aspitia,
A.
Lyss,
C.
Cirrincione,
E.
Mayer,
M.
Naughton,
R.
Layman,
L.
Carey,
R.
Somer,
E.
Perez,
C.
Hudis,
E.
Winer
(2012)
CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 18_suppl
-
S.
Spazzapan,
D.
Crivellari,
Philippe
Bédard,
D.
Lombardi,
G.
Miolo,
S.
Scalone,
A.
Veronesi
(2011)
Therapeutic management of breast cancer in the elderly
Expert Opinion on Pharmacotherapy, 12
-
(2008)
Adjuvant treatment of breast cancer in the elderly. Understanding and addressing the challenges
Oncology (Williston Park), 22
-
(2000)
Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-receptor positive advanced breast cancer
ClinicalTrials.gov [Internet]
-
H.
Burstein
(2011)
Novel agents and future directions for refractory breast cancer.
Seminars in oncology, 38 Suppl 2
-
Anthony
Howell,
J.
Robertson,
J.
Albano,
A.
Aschermannová,
L.
Mauriac,
U.
Kleeberg,
I.
Vergote,
B.
Erikstein,
A.
Webster,
Charles
Morris
(2002)
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 16
-
(2000)
Study of fulvestrant +/− everolimus in post-menopausal, hormone-receptor + metastatic breast Ca resistant to AI (PrE0102)
ClinicalTrials.gov [Internet]
-
A.
Leo,
G.
Jerusalem,
L.
Petruželka,
R.
Torres,
I.
Bondarenko,
R.
Khasanov,
D.
Verhoeven,
J.
Pedrini,
I.
Smirnova,
M.
Lichinitser,
K.
Pendergrass,
Sally
Garnett,
J.
Lindemann,
F.
Sapunar,
Miguel
Martín
(2010)
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 30
-
(2015)
PhIb BKM120 or BEZ235+endocrine treatment in post-menopausal patients with hormone receptor + metastatic breast cancer Available at: http://clinicaltrials
-
Y.
Chia,
Cynthia
Ma
(2009)
Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT
Breast Diseases: A Year Book Quarterly, 20
-
(2009)
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Cochrane Database Syst Rev, 4
-
D.
Yardley,
R.
Ismail-Khan,
B.
Melichar,
M.
Lichinitser,
P.
Munster,
P.
Klein,
S.
Cruickshank,
K.
Miller,
M.
Lee,
J.
Trepel
(2013)
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 17
-
(2015)
Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-receptor positive advanced breast cancer Available at: http://clinicaltrials
-
D.
Crivellari,
K.
Gray,
S.
Dellapasqua,
F.
Puglisi,
K.
Ribi,
K.
Price,
I.
Láng,
L.
Gianni,
S.
Spazzapan,
G.
Pinotti,
J.
Lüthi,
R.
Gelber,
M.
Regan,
M.
Colleoni,
M.
Castiglione‐Gertsch,
R.
Maibach,
M.
Rabaglio,
A.
Coates,
A.
Goldhirsch
(2013)
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial.
Breast, 22 2
-
S.
Demissie,
R.
Silliman,
T.
Lash
(2001)
Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 2
-
(2000)
Study of efficacy and safety of LEE011 in postmenopausal women with advanced breast cancer (MONALEESA-2)
ClinicalTrials.gov [Internet]
-
S.
Diab,
R.
Elledge,
G.
Clark
(2000)
Tumor characteristics and clinical outcome of elderly women with breast cancer.
Journal of the National Cancer Institute, 92 7
-
A.
Leo,
G.
Jerusalem,
L.
Petruželka,
R.
Torres,
I.
Bondarenko,
R.
Khasanov,
D.
Verhoeven,
J.
Pedrini,
I.
Smirnova,
M.
Lichinitser,
K.
Pendergrass,
L.
Malorni,
Sally
Garnett,
Y.
Rukazenkov,
Miguel
Martín
(2013)
Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial
JNCI Journal of the National Cancer Institute, 106
-
M.
Hamaker,
C.
Seynaeve,
J.
Nortier,
M.
Wymenga,
E.
Maartense,
E.
Boven,
A.
Leeuwen-Stok,
S.
Rooij,
B.
Munster,
C.
Smorenburg
(2013)
Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study.
Breast, 22 4
-
(2000)
PhIb BKM120 or BEZ235+endocrine treatment in post-menopausal patients with hormone receptor + metastatic breast cancer
ClinicalTrials.gov [Internet]
-
D.
Mauri,
N.
Pavlidis,
N.
Polyzos,
J.
Ioannidis
(2006)
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Journal of the National Cancer Institute, 98 18
-
(1975)
Available at: http://seer.cancer.gov/csr
-
A.
Vanderwalde,
A.
Hurria
(2012)
Early breast cancer in the older woman.
Clinics in geriatric medicine, 28 1
-
P.
Marchei,
V.
Bianco,
E.
Pignatelli,
S.
Chiodini,
D.
Santini,
E.
Carico,
M.
Marchei,
A.
Vecchione
(1996)
Adjuvant treatment for breast cancer in the elderly.
Anticancer research, 16 2
-
(2015)
Letrozole and CDK 4/6 inhibitor for ER positive, HER2 negative breast cancer in postmenopausal women Available at: http://clinicaltrials
-
A.
Bardia,
Erin
Arieas,
Zhe
Zhang,
A.
DeFilippis,
Karineh
Tarpinian,
S.
Jeter,
A.
Nguyen,
N.
Henry,
D.
Flockhart,
D.
Hayes,
J.
Hayden,
A.
Storniolo,
D.
Armstrong,
N.
Davidson,
J.
Fetting,
P.
Ouyang,
A.
Wolff,
R.
Blumenthal,
M.
Ashen,
V.
Stearns
(2012)
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer
Breast Cancer Research and Treatment, 131
-
(2000)
Letrozole and CDK 4/6 inhibitor for ER positive, HER2 negative breast cancer in postmenopausal women
ClinicalTrials.gov [Internet]
-
S.
Burdette-Radoux,
H.
Muss
(2006)
Adjuvant chemotherapy in the elderly: whom to treat, what regimen?
The oncologist, 11 3
-
R.
Siegel,
D.
Naishadham,
A.
Jemal
(2013)
Cancer statistics, 2013
CA: A Cancer Journal for Clinicians, 63
-
J.
Coebergh,
M.
Janssen‐Heijnen,
P.
Razenberg
(1998)
Prevalence of co-morbidity in newly diagnosed patients with cancer: a population-based study.
Critical reviews in oncology/hematology, 27 2
-
K.
Dittus,
H.
Muss
(2007)
Management of the frail elderly with breast cancer.
Oncology, 21 14
-
GCC 0901 -study of how well letrozole works in combination with lapatinib followed by an addition of everolimus in postmenopausal women with advanced endocrine resistant breast cancer
-
(2011)
Early breast cancer in the older woman
Oncologist, 16